Follow up to the Previous Dipshit of the day: Turing Pharmaceuticals of New York

Here is the previous posting link on September 19, 2015:

“The drug, called Daraprim, was acquired in AUGUST by Turing Pharmaceuticals, a start-up run by a former hedge fund manager. Turing immediately raised the price to $750 a tablet from $13.50, bringing the annual cost of treatment for some patients to hundreds of thousands of dollars.”

Oh, the CEO is a former hedge-fund manager. Why am I not surprised? He must need a new house on the Riviera or maybe an upgrade on his private jet.

From their mission statement: “We are dedicated to helping patients, who often have limited or no effective treatment options, by developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas.” But this drug was neither developed nor commercialized by Turing Pharmaceuticals.

Notice the two legislators questioning this practice: “In August, two members of Congress investigating generic drug price increases wrote to Valeant Pharmaceuticals after that company acquired two heart drugs, Isuprel and Nitropress, from Marathon Pharmaceuticals and promptly raised their prices by 525 percent and 212 percent respectively. Marathon had acquired the drugs from another company in 2013 and had quintupled their prices, according to the lawmakers, Senator Bernie Sanders, the Vermont independent who is seeking the Democratic nomination for president, and Representative Elijah E. Cummings, Democrat of Maryland.”

Martin Shkreli CEO,
Turing Pharmaceuticals LLC
1177 Avenue of the Americas, 39th Floor
New York, NY 10036

Tel: 1.646.356.5577

Craig Rothenberg
Chief Communication Officer

Thank you to Mary Sweeny and Paddy Horton for the above information on this turd of a man…….


    1. We can always hope he gets a major illness and he cannot afford his own medicine.

watcha gotta say?

This site uses Akismet to reduce spam. Learn how your comment data is processed.